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Single BCG vaccination has been considered as a protective factor against asthma. However
the effect of a second dose of BCG on the prevalence rate of asthma and asthmaeallergic
rhinitiseeczema comorbidity has not been studied exclusively among adolescents. In this
ISAAC protocol-based cross sectional study we assessed the association between one single
versus two doses of BCG among 2213 individuals aged 13e14 years old. We found no association
between BCG revaccination and asthma, associated (OR Z 0.68, 95% CI, 0.37e1.25) or not to
allergic rhinitis and/or atopic eczema (OR Z 1.07, 95% CI, 0.84e1.36).
ª 2012 Elsevier Ltd. All rights reserved.Introduction
Bacillus CalmetteeGue´rin (BCG) vaccination is purported to
promote T lymphocyte polarization, and to induce TH1
lymphocytes to produce antagonist cytokines to the ones
that promote atopic conditions.1 Considering that atopy is
a well-known risk factor for asthma, single BCG vaccinationces Postgraduate Program, Feder
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2.10.009has been studied as a protective factor against that
disease. In the study of Shirakawa et al. positive tuberculin
response predicted a lower incidence rate of asthma,1
similarly to the results from a recent published meta-
analysis.2 Furthermore, four other published studies found
conflicting results of the effect of BCG vaccination on the
prevalence of asthma.3e6al University of Sa˜o Joa˜o del-Rei, Rua Sebastia˜o Gonc¸alves Coelho,
.ufmg.br (P. Camargos).
.
Table 1 Logistic regression analysis adjusted for cluster
effect, for BCG revaccination and both current and ‘atopic’
asthma.
BCG scar Current asthma Current ‘atopic’ asthma
n/N (%) OR (95% CI) n/N (%) OR (95% CI)
One scar 128/768
(16.7)
1 29/768 (3.8) 1
Two scar 269/1445
(18.6)
1.07
(0.84e1.36)
64/1445
(4.4)
0.68
(0.37e1.25)
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Between 2001and2002 several surveys on asthmaandallergic
diseases were conducted in Brazil and other countries taking
part of the phase three of the ISAAC (International Study of
Asthma and Allergies in Childhood) that included school-
children and adolescents.7 We took the opportunity of the
ISAAC survey carried out in Belo Horizonte, Southeastern
Brazil, to assess a poorly studied association between BCG
revaccination (i.e., a second vaccination administered 7e10
years after the neonatal one and 3e8 years before data
collection) and the prevalence of asthma, allergic rhinitis and
atopic eczema among teenagers (13e14 years old).
In the present study, all the adolescents from 14
randomly selected public schools were recruited. Data
were collected through a translated and validated Portu-
guese version of the ISAAC questionnaire.7 Subjects were
classified as having one scar (related to the dose received
within the first weeks of life) or two BCG scars (i.e.,
revaccinated from 6e7 to 10 years of age). Scars were
considered as markers of BCG vaccination if they had
a typical aspect, with 3e10 mm of diameter, and located in
the lower insertion of the right deltoid muscle.8 Scar
characterization was verified by trained health workers.
The main outcomes were predefined according to the
ISAAC protocol, i.e., current asthma was defined in the case
of an affirmative answer to the following question “Have you
had wheezing or whistling chest in the past 12 months?”
while the presence of allergic rhinitis was considered if the
adolescent responded affirmatively and simultaneously to
the both following questions: 1) “In the past 12months, have
you had a problem with sneezing, or a runny, or a blocked
nose when you did not have a cold or flu?” and 2) “In the past
12 months, has this nose problem been accompanied by
itchy-watery eyes?”. Flexural lesion suggestive of eczema
was defined if there were affirmative answers to all the 3
questions, as follows: 1) “Have you ever had an itchy rash
which was coming and going for at least 6 months?” and 2) If
yes, “Have you had this itchy rash at any time in the last 12
months?” and 3) If yes, “Has this itchy rash at any time
affected any of the following places, as follows, the folds of
the elbows, behind the knees, in front of the ankles, under
the buttocks, or around the neck, ears, or eyes?” The
concomitant presence of asthma and allergic rhinitis and/or
eczema, as defined above, was considered as a proxy of
‘atopic’ asthma. Our work hypothesis was that BCG revac-
cination has not any effect on asthma prevalence.
The association between BCG revaccination and the
prevalence of asthma was estimated through odds ratios
(OR), adjusted for cluster effect and obtained through
logistic regression with random-effects, considering each
school as a cluster.
Results
The original sample encompassed 2771 adolescents, but
558 of them (20.1%) were excluded due to missing data. In
the remaining 2213 included in the final analysis, there
were 47.7% boys, and 1445 (65.3%) of them were revacci-
nated (i.e., had two BCG scars), while 768 had one single
BCG scar (34.7%).Both, current asthma and ‘atopic’ asthma, were re-
ported by 394 (17.8%), and 93 (4.2%) participants, respec-
tively. Among them, 375 (95.2%) had also reported at least
one of the following: diagnosis of asthma ever, wheezing
with exercise in the last 12 months, more than 3 episodes of
wheezing in the last 12 months, and waking up at night
because of wheezing in the last 12 months, demonstrating
a high likelihood of suffering from asthma.
From the adolescents with current asthma and from the
ones with current asthma and allergic rhinitis and/or atopic
eczema, 67.7% and 68.0% were revaccinated, respectively.
As shown in Table 1, no association between revaccination
and presence of symptoms of current asthma and ‘atopic’
asthma in the studied population was found. Moreover,
there was no association when each school was evaluated
separately (data not shown).
Discussion
Prevalence of current asthma in Brazilian adolescents is by
20% despite of virtually 100% single BCG vaccination
coverage in the first weeksemonths of life. These epide-
miological data are in accordance with the results obtained
in the present study. Sarinho et al. observed similar results
in a Brazilian retrospective cohort study in which the mean
age of the studied population was 25 years, which hampers
comparison with our results.6
According to a recent published meta-analysis2 and the
study carried out by Linehan et al.,9 single BCG vaccination
could be a protective factor for asthma, but probably
genetic and environmental factors might be involved with
this effect. For instance, tobacco exposure, air pollution,
intestinal parasites and viral respiratory infections probably
affect asthma development, preventing the potential
protective effect of BCG on both atopic and non-atopic
asthma in our study population. Differently from results re-
ported by Shirakawa et al., concomitant atypical mycobac-
teria infection is not frequent in Southeastern Brazil, and
therefore exposure to nontuberculous environmental
mycobacteria was probably not a confounding in our results.
Taken into account that we randomly selected 14 schools,
it is reasonable to assume that these previously mentioned
factors were equally distributed into our studied population,
i.e., single or two BCG-related scar groups and probably did
not interfered in the final results. We argue that the multi-
factorial (and not only BCG vaccination or revaccination
itself) pathogenesis of asthma could explain the controver-
sial results verified in studies that assessed the relationship
between BCG vaccination and asthma conducted in different
BCG revaccination against asthma 319countries and therefore they can not be generalized. Further
studies on this subject in different settings would be
necessary to a better understanding of this issue.
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